Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report

Author(s): Luca Gallelli, Andzelika Michniewicz, Roberta Stefanelli, Roberto Cannataro, Paola Longo, Mariarita Perri, Erika Cione, Maria C. Caroleo

Journal Name: Current Drug Safety

Volume 11 , Issue 2 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Treatment guidelines recommend omega-3 with Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) content not above 85% in patients with high plasma levels of triglycerides. Since the different up to date formulation of omega-3 available in commerce must be similar to clinical efficacy and safety, herein, we report the case a 52-year-old woman who presented clinical inefficacy using Olevia® omega-3 treatment. Clinical evaluation excluded the presence of intestinal or systemic diseases able to reduce the drug absorption. Switching the therapy from (Olevia®) to an equivalent omega-3 formulation (Esapent®), we documented a decrease in her plasma triglycerides levels. In order to evaluate a possible difference between these formulations we performed a single blind in vitro dissolution test using three pills for each formulation of omega-3 (Olevia®, Esapent® and another one chosen between the several formulations available in commerce: DOC Generic®) that revealed a significant difference (>20%) in the dissolution time of three different omega- 3 commercially available drug formulation.

Keywords: Omega-3 formulation, clinical efficacy, clinical inefficacy, dissolution time.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 28 April, 2016
Page: [177 - 180]
Pages: 4
DOI: 10.2174/1574886311666151106120928
Price: $65

Article Metrics

PDF: 33
PRC: 1